Narrow Results

At the peak of the SARS epidemic in Hong Kong, hospital workers were under high risks of contraction of the infection. Herbal preparations had been used historically in China to treat influenza-like diseases. During the SARS outbreak, herbal preparations had been used jointly with standard modern treatment in China. As a means to protect the at-risk hospital workers, an innovative herbal formula was created and consumed by 3160 of them in two weeks. During the two weeks, symptoms and adverse effects were close monitored; 37 of them had their serum checked for immunological responses.

The results showed that none of the herb consumers contracted the infection, compared to 0.4% among the non-consumers. Adverse effects had been infrequent and mild. There were hardly any influenza-like symptoms and the quality of life improved. In the group who volunteered to have their immunological state checked, significant boosting effects were found. It was concluded that there might be a good indication for using suitable herbal preparations as a means of preventing influenza-like infection. The mode of preventive effect could be treatment of the infection at its very early stage instead of producing a period of higher immunological ability, as in the case of vaccination.

The effect of the political transition from a British Colony to a Special Administration Region of China in 1997 on the tradition of Chinese medicine is examined using historical reviews as well as interviews with various sectors of the population in Hong Kong. Results show that the political change has stimulated the formation of a location-specific Hong Kong Chinese medicine strongly characterized by both scientific and commercial elements developed from the culture of Chinese medicine.

Alcon’s New Eye Drops Offers More Long-lasting Relief for Dry Eyes.

Carl Zeiss Opens New Shanghai Showroom.

Allergan’s Lumigan Receives Positive Opinion for Approval in Europe.

Australian Optical Retailer OPSM Sells Ten Stores to Sunglass Hut.

Bausch & Lomb Clearwater Plant Named Center of Excellence for Lathing Technology.

Santen — The Leading Prescription Ophthalmic Pharmaceutical Firm in Japan.

Always Top — An ISO9002 Quality Assured Eyewear Firm in Hong Kong.

Nanyang Optical — One of the Largest Optical Retail Chains in Singapore.

SARS Strikes.

Eradicating Pig Pneumonia.

Hong Kong Unveils New Center for Health Protection.

Supreme Court Holds State Responsible for Minamata Outbreak.

Asian Cord Blood Banks Form Consortium.

This article touches on traditional Chinese medicine in the treatment of diabetes.

The article discusses on what the Hong Kong government are doing to boost biomedical investments. It touches briefly on the biotechnology market and Hong Kong government policy for Innovation and Technology. It also includes some examples of biotech companies.

Infinitus Establishes Three Additional Scientific Research Platforms to Facilitate Its Product Innovation.

BGI Partners with NRGene to Provide Broadest Genomic Analysis Available.

CHINA AID - A Platform for Chinese Senior Care Industry.

Modern Biotechnological Tools Contribute to Biodiversity Conservation.

Older Adults Use Brain Regions Involved in Speaking to Compensate for Bad Hearing.

Chinese Scientists Discover Molecules to Repair Organs.

CAS Sits Atop of Nature Index 2016 Rising Star List.

Chinese Researchers to Develop 3D Skin Printing Technology.

Varian Chosen to Equip First Government Owned Proton Centre in China.

HONG KONG NEWS – Amgen Launches Commercial Office in Hong Kong.

Chinese Researchers Demonstrate that Icotinib Creates Better Progression-Free Survival with Fewer Side Effects than Whole Brain Radiation in Non-Small Cell Lung Cancer Patients with Brain Metastases.

Depressed Patients Are Less Responsive to Chemotherapy.

Sanofi and JHL Biotech Announced Strategic Biologics Alliance in China.

Chinese Scientists Developed Cancer Breath Test.

BGI Opens Seattle Office for North America Expansion.

Mederi’s Stretta Therapy for GERD Approved in China.

HONG KONG NEWS – Experts Call for Urgent Multi-Stakeholders Collaboration in the Development of an Integrated Cancer Strategy to Safeguard the Sustainability of Hong Kong's Health Care System.

HONG KONG NEWS – Uni-Bio Science in Multiple Drug Co-Development Deal with Beijing Sun-Novo.

HONG KONG NEWS – Immunotherapy with Pembrolizumab Deemed Cost-Effective for Advanced Melanoma Patients in Hong Kong.